News:
Inovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
Inovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Investor information
Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.
Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.
Inovio's technology is IMMUNO-INGENUITY in action
Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.